– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022–
– IND Clearance Achieved for CFT8634, a Degrader Targeting BRD9; On Track to Initiate Phase 1 Trial in Synovial Sarcoma and SMARCB1-null Solid Tumors in 1H 2022–
– CFT1946, a BRAF V600X Degrader, Advancing Towards the Clinic with IND Submission and Phase 1 Trial Initiation Planned for 2H 2022–
– Strengthened Leadership Team with Addition of Scott Boyle, Ph.D., MBA as Chief Business Officer–
–Year-End Cash, Cash Equivalents, and Marketable Securities Expected to Provide Runway to End of 2024–
